Martin Huber
2020 - Xilio Therapeutics
In 2020, Martin Huber earned a total compensation of $963.6K as President of R&D and Chief Medical Officer at Xilio Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $159,120 |
|---|---|
| Option Awards | $501,101 |
| Salary | $301,467 |
| Other | $1,889 |
| Total | $963,577 |
Huber received $501.1K in option awards, accounting for 52% of the total pay in 2020.
Huber also received $159.1K in non-equity incentive plan, $301.5K in salary and $1.9K in other compensation.
Rankings
In 2020, Martin Huber's compensation ranked 8,790th out of 13,090 executives tracked by ExecPay. In other words, Huber earned more than 32.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,790 out of 13,090 | 33rd |
Division Manufacturing | 3,746 out of 5,618 | 33rd |
Major group Chemicals And Allied Products | 1,512 out of 2,251 | 33rd |
Industry group Drugs | 1,317 out of 1,951 | 33rd |
Industry Pharmaceutical Preparations | 973 out of 1,456 | 33rd |
Source: SEC filing on April 26, 2022.
Huber's colleagues
We found one more compensation record of an executive who worked with Martin Huber at Xilio Therapeutics in 2020.
2020
René Russo
Xilio Therapeutics
Chief Executive Officer
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Xilio Therapeutics CEO René Russo's 2023 pay jumps 36% to $3M
April 25, 2024
Xilio Therapeutics CEO René Russo's 2022 pay falls 60% to $2.2M
April 25, 2023
Xilio Therapeutics CEO René Russo's 2021 pay jumps 118% to $5.5M
April 26, 2022